Published in Am J Med on March 01, 1975
Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol (2009) 2.45
The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol (2011) 1.38
Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant (2012) 1.31
Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial. J Clin Pathol (1984) 1.07
Idiopathic Fanconi syndrome with progressive renal failure: a case report and discussion. Yale J Biol Med (1990) 0.94
Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer (1986) 0.90
Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol (2015) 0.86
Acquired Fanconi syndrome in patients with Legionella pneumonia. BMC Nephrol (2013) 0.85
Transient Fanconi syndrome in Quarter horses. Can Vet J (2014) 0.80
Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome. J Am Soc Nephrol (2015) 0.80
Tumor-Induced Osteomalacia. Transl Endocrinol Metab (2015) 0.79
Spectrum of monoclonal gammapathies in Andhra Pradesh. Indian J Clin Biochem (2001) 0.77
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. Leukemia (2016) 0.75
Medical Staff Conference. Tubulo-interstitial nephropathies--a pathophysiologic approach. West J Med (1980) 0.75
Bilineal Acute Leukemia Associated With Fanconi Syndrome: The First Case Report. Iran J Pediatr (2016) 0.75
Light-chain nephropathy in patient with renal carcinoma. Br Med J (Clin Res Ed) (1981) 0.75
Hypophosphataemic osteomalacia due to urinary kappa light chain. J R Soc Med (1993) 0.75
Light chain proximal tubulopathy with cast nephropathy in a case of multiple myeloma. Indian J Nephrol (2015) 0.75
The kidney in multiple myeloma. West J Med (1978) 0.75
Adult Fanconi syndrome progressing to multiple myeloma. J Clin Pathol (1984) 0.75
Acquired Fanconi syndrome in a dog exposed to jerky treats in Japan. J Vet Med Sci (2015) 0.75
A case of Fanconi syndrome accompanied by crystal depositions in tubular cells in a patient with multiple myeloma. Kidney Res Clin Pract (2014) 0.75
[Lupus nephritis with crystal structures in glomerulopathy ]. Pathologe (2003) 0.75
Multiple and ancient origins of the domestic dog. Science (1997) 27.18
Multiple myeloma: review of 869 cases. Mayo Clin Proc (1975) 4.59
Amyloidosis: review of 236 cases. Medicine (Baltimore) (1975) 3.39
Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc (1983) 3.22
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med (1978) 3.08
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood (1993) 2.98
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med (1978) 2.70
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med (1970) 2.61
Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol (1991) 2.59
New histochemical method for morphologic diagnosis of early stages of myocardial ischemia. Mayo Clin Proc (1971) 2.58
Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome. Mayo Clin Proc (1973) 2.56
Doppler index combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol (1996) 2.48
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia (2003) 2.28
"Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med (1982) 2.24
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis (1983) 2.22
Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet (1982) 2.21
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int (2008) 2.21
Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med (1983) 2.13
A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med (1994) 2.11
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Thalidomide as initial therapy for early-stage myeloma. Leukemia (2003) 2.02
Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest (1976) 1.96
Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol (1994) 1.88
Identification of a major basic protein in guinea pig eosinophil granules. J Exp Med (1973) 1.87
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Smoldering multiple myeloma. N Engl J Med (1980) 1.77
Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am (1999) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int (1988) 1.72
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood (1985) 1.67
Diffuse glomerulonephritis associated with infected ventriculoatrial shunt. N Engl J Med (1968) 1.67
Plasma cell leukemia. Report on 17 cases. Arch Intern Med (1974) 1.66
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia (2007) 1.66
Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) (1991) 1.66
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood (1996) 1.65
Long-term intermittent hemodialysis for chronic renal failure. Mayo Clin Proc (1966) 1.65
Phylogenetic relationships, evolution, and genetic diversity of the domestic dog. J Hered (1999) 1.62
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia (2012) 1.60
Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. Amyloid (1999) 1.59
Thalidomide in the treatment of plasma cell malignancies. J Clin Oncol (2001) 1.59
Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia (2008) 1.56
Chronic idiopathic intestinal pseudo-obstruction. Am J Med (1970) 1.55
The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med (1981) 1.54
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood (1996) 1.54
Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc (1989) 1.52
Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol (1996) 1.52
Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med (1996) 1.51
Plasma cell leukemia: an evaluation of response to therapy. Am J Med (1987) 1.51
Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys (1989) 1.51
Immunologic mechanisms in systemic vasculitis. Mayo Clin Proc (1976) 1.50
Systemic giant-cell arteritis with polymyalgia rheumatica, reversible abnormalities of liver function. JAMA (1973) 1.48
Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc (2000) 1.47
Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc (1993) 1.47
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
Cytomegalovirus studies of autopsy tissue. I. Virus isolation. Am J Clin Pathol (1975) 1.47
Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A (2000) 1.46
SLE nephropathy in a patient with HIV infection: case report and review of the literature. J Rheumatol (1996) 1.46
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood (1972) 1.45
Why better prognostic factors for multiple myeloma are needed. Blood (1994) 1.44
Osteosclerotic myeloma and peripheral neuropathy. Neurology (1983) 1.44
Cytomegalovirus studies of autopsy tissue. II. Incidence of inclusion bodies and related pathologic data. Am J Clin Pathol (1975) 1.44
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Prevalence of monoclonal protein in peripheral neuropathy. Neurology (1981) 1.41
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. J Thorac Cardiovasc Surg (1975) 1.41
Yusuf ibn al-Kindi. JAMA (1975) 1.39
Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis (1995) 1.39
Renal biopsy in clinical practice. Mayo Clin Proc (1994) 1.39
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia (2006) 1.39
Factor-X deficiency in amyloidosis: a critical review. Am J Hematol (1981) 1.38
Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol (1989) 1.38
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia (2011) 1.38
Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia (2001) 1.36
Histologic demonstration of fat emboli in aseptic necrosis associated with hypercortisonism. Mayo Clin Proc (1969) 1.34
Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg (1992) 1.32
Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation (1991) 1.32
Significance of extreme elevation of erythrocyte sedimentation rate. JAMA (1967) 1.31
The progression of vesicoureteral reflux nephropathy. Ann Intern Med (1980) 1.31
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia (2011) 1.31
Long-term survival in multiple myeloma. N Engl J Med (1983) 1.30
Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30
Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc (2000) 1.30
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood (1986) 1.29
Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry (1996) 1.28
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest (1977) 1.28
High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia (2012) 1.27
Response rates and survival in primary systemic amyloidosis. Blood (1991) 1.27